UA94427C2 - Фармацевтическая композиция для местного лечения неоваскулярных расстройств глаз - Google Patents

Фармацевтическая композиция для местного лечения неоваскулярных расстройств глаз

Info

Publication number
UA94427C2
UA94427C2 UAA200805311A UAA200805311A UA94427C2 UA 94427 C2 UA94427 C2 UA 94427C2 UA A200805311 A UAA200805311 A UA A200805311A UA A200805311 A UAA200805311 A UA A200805311A UA 94427 C2 UA94427 C2 UA 94427C2
Authority
UA
Ukraine
Prior art keywords
ocular neovascular
pharmaceutical composition
topical treatment
neovascular disorders
administration
Prior art date
Application number
UAA200805311A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ричард Энтони Бриганди
Марк Левик
Вилльям Генри Миллер
Original Assignee
Смиткляйн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смиткляйн Бичам Корпорейшн filed Critical Смиткляйн Бичам Корпорейшн
Publication of UA94427C2 publication Critical patent/UA94427C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

Заявленное изобретение касается способов лечения глазных неоваскулярных расстройств у млекопитающих. Способ состоит в назначении указанному млекопитающему соединений формулы (I) или их солей, или сольватов.(I)
UAA200805311A 2005-11-29 2006-11-29 Фармацевтическая композиция для местного лечения неоваскулярных расстройств глаз UA94427C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74047805P 2005-11-29 2005-11-29

Publications (1)

Publication Number Publication Date
UA94427C2 true UA94427C2 (ru) 2011-05-10

Family

ID=38037895

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200805311A UA94427C2 (ru) 2005-11-29 2006-11-29 Фармацевтическая композиция для местного лечения неоваскулярных расстройств глаз

Country Status (28)

Country Link
US (1) US20080293691A1 (ru)
EP (2) EP1968594B1 (ru)
JP (1) JP5180834B2 (ru)
KR (1) KR20080071188A (ru)
CN (1) CN101370505B (ru)
AT (1) ATE482708T1 (ru)
AU (2) AU2006320535B2 (ru)
BR (1) BRPI0619057A2 (ru)
CA (1) CA2631173A1 (ru)
CR (1) CR10010A (ru)
CY (1) CY1111047T1 (ru)
DE (1) DE602006017261D1 (ru)
DK (1) DK1968594T3 (ru)
EA (1) EA016227B1 (ru)
ES (2) ES2392030T3 (ru)
HK (1) HK1121386A1 (ru)
HR (1) HRP20100559T1 (ru)
IL (1) IL191027A0 (ru)
MA (1) MA30044B1 (ru)
MX (1) MX2008006379A (ru)
MY (1) MY144750A (ru)
NO (1) NO20081963L (ru)
NZ (1) NZ568075A (ru)
PL (1) PL1968594T3 (ru)
PT (1) PT1968594E (ru)
SI (1) SI1968594T1 (ru)
UA (1) UA94427C2 (ru)
WO (1) WO2007064752A2 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711696C (en) 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
EP2257538B1 (en) * 2008-03-06 2016-04-27 GlaxoSmithKline LLC Process for the preparation of benzodiazepine derivatives
WO2010088548A1 (en) 2009-01-29 2010-08-05 Forsight Labs, Llc Posterior segment drug delivery
CA2768237A1 (en) * 2009-07-16 2011-01-20 Glaxo Wellcome Manufacturing Pte Ltd Treatment method
WO2011050159A1 (en) * 2009-10-23 2011-04-28 Glaxo Wellcome Manufacturing Pte Ltd Compositions and processes
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
UY33367A (es) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
US20120129847A1 (en) * 2010-10-07 2012-05-24 Kevin Gene Peters Compositions and methods for treating ocular edema, neovascularization and related diseases
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
WO2013000917A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing regorafenib
JP2014518232A (ja) 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー ソラフェニブを含有する眼科用局所医薬組成物
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
LT2755600T (lt) 2011-09-16 2021-04-26 Forsight Vision4, Inc. Skysčio pakeitimo aparatas
RU2616500C2 (ru) 2011-10-31 2017-04-17 Новартис Аг Композиция пазопаниба
AU2012343759A1 (en) 2011-12-01 2014-06-26 Glaxo Group Limited Methods of treatment and prevention of eye diseases
CN102657655B (zh) * 2012-05-17 2014-05-21 大连理工大学 嘧啶胺类化合物在制备乙酰胆碱酯酶抑制剂中的应用
EP2858628A1 (en) 2012-06-25 2015-04-15 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing sunitinib
EP2935250B1 (en) 2012-12-17 2018-03-28 Sun Pharmaceutical Industries Limited Process for the preparation of pazopanib or salts thereof
WO2014097152A1 (en) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of pazopanib or salts thereof
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10730859B2 (en) 2013-11-05 2020-08-04 Laurus Labs Limited Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3177289A4 (en) 2014-08-08 2018-03-21 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
JP6499290B2 (ja) * 2014-09-09 2019-04-10 ヘレラ アルトゥーロ ソリス メラニンならびにメラニン類似体、前駆体、および誘導体による眼疾患、眼障害および眼症状の治療および予防のための方法
AU2015346450B2 (en) 2014-11-10 2020-01-30 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
AU2017205185B2 (en) 2016-01-07 2022-03-31 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
EP3439591B1 (en) 2016-04-05 2020-09-23 ForSight Vision4, Inc. Implantable ocular drug delivery devices
CN106565688B (zh) * 2016-11-11 2018-08-31 重庆医科大学 帕唑帕尼二聚体及其制备方法和用途
WO2019075270A1 (en) 2017-10-12 2019-04-18 Amesino Llc VEGFR ANTIBODY LIGHT CHAIN FUSION PROTEIN
KR20200093581A (ko) 2017-11-21 2020-08-05 포사이트 비젼4, 인크. 확장 가능한 포트 전달 시스템을 위한 유체 교환 기기 및 사용 방법
CN110878089A (zh) * 2018-09-05 2020-03-13 江苏豪森药业集团有限公司 一种盐酸帕唑帕尼的制备方法
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5322691A (en) 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
DE3905050A1 (de) 1989-02-18 1990-08-30 Lohmann Therapie Syst Lts Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (ii)
US4946450A (en) 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5290892A (en) 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
FR2690846B1 (fr) 1992-05-05 1995-07-07 Aiache Jean Marc Forme galenique pour administration oculaire et procede de preparation.
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5710165A (en) 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
AUPM897594A0 (en) 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
ES2191719T3 (es) 1994-11-10 2003-09-16 Univ Kentucky Res Found Dispositivo implantable y recargable de descarga controlada para suministrar farmacos directamente a una parte interna del cuerpo.
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5824073A (en) 1996-03-18 1998-10-20 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
US5743274A (en) 1996-03-18 1998-04-28 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular members
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
UA60311C2 (ru) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагонисты рецептора витронектина
US20030125317A1 (en) * 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
ES2232005T3 (es) 1997-08-11 2005-05-16 Allergan, Inc. Dispositivo de implante biodegradable esteril que contiene retinoide con biocompatibilidad mejorada y metodo de preparacion.
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6146366A (en) 1998-11-03 2000-11-14 Ras Holding Corp Device for the treatment of macular degeneration and other eye disorders
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6660960B2 (en) 1999-12-28 2003-12-09 K. K. Endo Seisakusho Method for manufacturing golf club
US6719750B2 (en) 2000-08-30 2004-04-13 The Johns Hopkins University Devices for intraocular drug delivery
DK2311825T3 (en) * 2000-12-21 2016-01-18 Novartis Ag Pyrimidinamines AS ANGIOGENESEMODULATORER
US7592016B2 (en) 2001-06-28 2009-09-22 Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US7749528B2 (en) 2001-08-29 2010-07-06 Ricardo Azevedo Pontes De Carvalho Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
WO2003020172A1 (en) 2001-08-29 2003-03-13 De Carvalho Ricardo A P An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
JP2005525408A (ja) * 2002-05-03 2005-08-25 アルコン，インコーポレイテッド アンフェナクまたはネパフェナクを用いる血管内皮増殖因子媒介性血管障害の処置方法
EP1515955A4 (en) * 2002-06-17 2006-05-03 Smithkline Beecham Corp CHEMICAL PROCESS
JP2007532658A (ja) * 2004-04-16 2007-11-15 スミスクライン ビーチャム コーポレーション がんの治療方法
WO2006047325A1 (en) * 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2006117666A2 (en) * 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery

Also Published As

Publication number Publication date
CA2631173A1 (en) 2007-06-07
CR10010A (es) 2008-11-03
DK1968594T3 (da) 2010-12-13
AU2010249187A1 (en) 2011-01-06
SI1968594T1 (sl) 2011-01-31
EP2329821A1 (en) 2011-06-08
NO20081963L (no) 2008-08-26
HRP20100559T1 (hr) 2010-11-30
EP1968594B1 (en) 2010-09-29
CN101370505B (zh) 2012-03-21
MX2008006379A (es) 2009-03-03
WO2007064752A2 (en) 2007-06-07
AU2006320535B2 (en) 2010-09-23
IL191027A0 (en) 2009-08-03
EA200801168A1 (ru) 2008-10-30
CN101370505A (zh) 2009-02-18
EP2329821B1 (en) 2012-08-22
HK1121386A1 (en) 2009-04-24
MA30044B1 (fr) 2008-12-01
CY1111047T1 (el) 2015-06-11
BRPI0619057A2 (pt) 2011-09-20
JP5180834B2 (ja) 2013-04-10
ES2392030T3 (es) 2012-12-04
MY144750A (en) 2011-10-31
ES2350858T3 (es) 2011-01-27
WO2007064752A3 (en) 2008-08-14
ATE482708T1 (de) 2010-10-15
EA016227B1 (ru) 2012-03-30
US20080293691A1 (en) 2008-11-27
PL1968594T3 (pl) 2011-03-31
NZ568075A (en) 2010-12-24
KR20080071188A (ko) 2008-08-01
EP1968594A2 (en) 2008-09-17
AU2006320535A1 (en) 2007-06-07
JP2009517396A (ja) 2009-04-30
PT1968594E (pt) 2010-11-18
DE602006017261D1 (de) 2010-11-11

Similar Documents

Publication Publication Date Title
UA94427C2 (ru) Фармацевтическая композиция для местного лечения неоваскулярных расстройств глаз
TW200716139A (en) Methods and compositions for managing psychotic disorders
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
EP2526933A3 (en) Inhibitors of bruton's tyrosine kinase
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
MXPA05013637A (es) Inhibidores gsk-3 y usos de los mismos.
SI1954281T1 (sl) Postopek zdravljenja raka
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
WO2007143483A3 (en) Combination of pazopanib and lapatinib for treating cancer
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
WO2007063384A3 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
CA2473202A1 (en) Pharmaceutical composition for regeneration of cirrhotic liver
BRPI0507802A (pt) composto, composição, e, método para tratar inflamação ou um distúrbio metabólico
TW200616625A (en) Agent for prophylaxis or treatment of metabolic syndrome
AU2003257589A1 (en) Remedy for integration dysfunction syndrome